(Q40490960)

21 September 2017

title

Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group (English)

1 reference

cervical squamous cell carcinoma

21 September 2017

main subject

1 reference

1 reference

1 reference

1

1 reference

21 September 2017

4

Bradley J Monk

1 reference

21 September 2017

John A Blessing

2

1 reference

21 September 2017

Ramon McGehee

series ordinal

3

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

94

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

483-487

1 reference

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Chemoradiation for locally advanced cervical cancer: does it help?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.05.018

10.1016/J.YGYNO.2004.05.018

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference